The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study
- PMID: 24550173
- DOI: 10.1136/annrheumdis-2013-204627
The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study
Abstract
Objectives: To estimate the global burden of rheumatoid arthritis (RA), as part of the Global Burden of Disease 2010 study of 291 conditions and how the burden of RA compares with other conditions.
Methods: The optimum case definition of RA for the study was the American College of Rheumatology 1987 criteria. A series of systematic reviews were conducted to gather age-sex-specific epidemiological data for RA prevalence, incidence and mortality. Cause-specific mortality data were also included. Data were entered into DisMod-MR, a tool to pool available data, making use of study-level covariates to adjust for country, region and super-region random effects to estimate prevalence for every country and over time. The epidemiological data, in addition to disability weights, were used to calculate years of life lived with disability (YLDs). YLDs were added to the years of life lost due to premature mortality to estimate the overall burden (disability-adjusted life years (DALYs)) for RA for the years 1990, 2005 and 2010.
Results: The global prevalence of RA was 0.24% (95% CI 0.23% to 0.25%), with no discernible change from 1990 to 2010. DALYs increased from 3.3 million (M) (95% CI 2.6 M to 4.1 M) in 1990 to 4.8 M (95% CI 3.7 M to 6.1 M) in 2010. This increase was due to a growth in population and increase in aging. Globally, of the 291 conditions studied, RA was ranked as the 42nd highest contributor to global disability, just below malaria and just above iodine deficiency (measured in YLDs).
Conclusions: RA continues to cause modest global disability, with severe consequences in the individuals affected.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Similar articles
-
The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study.Ann Rheum Dis. 2014 Jul;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763. Epub 2014 Feb 19. Ann Rheum Dis. 2014. PMID: 24553908
-
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993280 Review.
-
The global burden of neck pain: estimates from the global burden of disease 2010 study.Ann Rheum Dis. 2014 Jul;73(7):1309-15. doi: 10.1136/annrheumdis-2013-204431. Epub 2014 Jan 30. Ann Rheum Dis. 2014. PMID: 24482302
-
Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1564-74. doi: 10.1016/S0140-6736(13)61530-5. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993281 Review.
-
Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the Global Burden of Disease Study 2019.Clin Rheumatol. 2023 Sep;42(9):2297-2309. doi: 10.1007/s10067-023-06628-2. Epub 2023 Jun 9. Clin Rheumatol. 2023. PMID: 37294370
Cited by
-
Network Pharmacology to Identify the Pharmacological Mechanisms of a Traditional Chinese Medicine Derived from Trachelospermum jasminoides in Patients with Rheumatoid Arthritis.Med Sci Monit. 2020 Aug 25;26:e922639. doi: 10.12659/MSM.922639. Med Sci Monit. 2020. PMID: 32840241 Free PMC article.
-
Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients.Rheumatology (Oxford). 2021 Dec 1;60(12):5765-5774. doi: 10.1093/rheumatology/keab251. Rheumatology (Oxford). 2021. PMID: 33725091 Free PMC article. Clinical Trial.
-
Secreted Osteoclastogenic Factor of Activated T Cells (SOFAT) Is Associated With Rheumatoid Arthritis and Joint Pain: Initial Evidences of a New Pathway.Front Immunol. 2020 Jul 28;11:1442. doi: 10.3389/fimmu.2020.01442. eCollection 2020. Front Immunol. 2020. PMID: 32849501 Free PMC article.
-
Oral Complementary Medicine Use among People with Inflammatory Arthritis: An Australian Rheumatology Association Database Analysis.Int J Rheumatol. 2020 Jun 5;2020:6542965. doi: 10.1155/2020/6542965. eCollection 2020. Int J Rheumatol. 2020. PMID: 32565819 Free PMC article.
-
Association of Chinese herbal medicine use with the depression risk among the long-term breast cancer survivors: A longitudinal follow-up study.Front Psychol. 2022 Aug 18;13:884337. doi: 10.3389/fpsyg.2022.884337. eCollection 2022. Front Psychol. 2022. PMID: 36059752 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical